Human EEF2K ELISA Kit (V2LY-0626-LY5683)

Beretta, S., Gritti, L., Ponzoni, L., Scalmani, P., Mantegazza, M., Sala, M., ... & Sala, C. (2022). Rescuing epileptic and behavioral alterations in a Dravet syndrome mouse model by inhibiting eukaryotic elongation factor 2 kinase (eEF2K). Molecular autism, 13(1), 1-22.

Onder, F. C., Siyah, P., Durdagi, S., Ay, M., & Ozpolat, B. (2022). Novel Etodolac Derivatives as Eukaryotic Elongation Factor 2 Kinase (eEF2K) Inhibitors for Targeted Cancer Therapy. RSC Medicinal Chemistry.

Ma, T. (2021). Roles of eukaryotic elongation factor 2 kinase (eEF2K) in neuronal plasticity, cognition, and Alzheimer disease. Journal of Neurochemistry.

Zhu, S., Liao, M., Tan, H., Zhu, L., Chen, Y., He, G., & Liu, B. (2021). Inhibiting Eukaryotic Elongation Factor 2 Kinase: An Update on Pharmacological Small-Molecule Compounds in Cancer. Journal of Medicinal Chemistry, 64(13), 8870-8883.

Zhang, B., Zou, J., Zhang, Q., Wang, Z., Wang, N., He, S., ... & Naman, C. B. (2021). Progress in the development of eukaryotic elongation factor 2 kinase (eEF2K) natural product and synthetic small molecule inhibitors for cancer chemotherapy. International Journal of Molecular Sciences, 22(5), 2408.

Karakas, D., & Ozpolat, B. (2020). Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target. Journal of Molecular Medicine, 98(6), 775-787.

Zhou, Y., Li, Y., Xu, S., Lu, J., Zhu, Z., Chen, S., ... & Shen, K. (2020). Eukaryotic elongation factor 2 kinase promotes angiogenesis in hepatocellular carcinoma via PI3K/Akt and STAT3. International journal of cancer, 146(5), 1383-1395.

Ng, T. H., Sham, K. W., Xie, C. M., Ng, S. S., To, K. F., Tong, J. H., ... & Cheng, C. H. (2019). Eukaryotic elongation factor-2 kinase expression is an independent prognostic factor in colorectal cancer. BMC cancer, 19(1), 1-9.

Jan, A., Jansonius, B., Delaidelli, A., An, Y. A., Ferreira, N., Smits, L. M., ... & Sorensen, P. H. (2018). Activity of translation regulator eukaryotic elongation factor-2 kinase is increased in Parkinson disease brain and its inhibition reduces alpha synuclein toxicity. Acta neuropathologica communications, 6(1), 1-17.

Pan, Z., Chen, Y., Liu, J., Jiang, Q., Yang, S., Guo, L., & He, G. (2018). Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy. European journal of medicinal chemistry, 144, 517-528.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols